Although our study partially demonstrated the clinical implications of SUSD2 in EGFR+ HER2+ breast cancer by showing that SUSD2 conferred a poorer survival to EGFR+ HER2+ breast cancer patients and that it was associated with EGFR and HER2 signaling, further mechanistic validation is necessary. This evidence concerns the gene EGFR and breast cancer.